Supriya Lifescience names Dr. Saloni Wagh as MD
Shivani Satish Wagh takes on the role of Joint Managing Director
Shivani Satish Wagh takes on the role of Joint Managing Director
EBITDA at Rs. 250 crore, up 47% YoY, with 35% EBITDA margin
Nelarabine is a nucleoside metabolic inhibitor indicated for the treatment of patients with T-cell acute lymphoblastic leukemia
Q1 FY25 revenues up 20% YoY to Rs. 1,002 crore
Q1 Consolidated operating profit Up 8.3%; revenue grows 7% to Rs 3,349 crore
Strong topline growth driven by solid performance across key brands.
The New Drug Application (NDA) includes data from the Phase III studies OASIS 1, 2 and 3 - showing elinzanetant significantly reduced the frequency and severity of moderate to severe vasomotor symptoms over 12 weeks compared to placebo
This product will be manufactured at Lupin’s Nagpur facility in India and will be supplied to low and middle-income countries
Performed an autologous bone marrow transplant, using the patient’s own cells to reduce the chances of infection and rejection
Granules India has reported total income of Rs. 1181.92 crores during the period ended June 30, 2024
Subscribe To Our Newsletter & Stay Updated